April 29 (Reuters) – Italy’s Chiesi has agreed to buy KalVista Pharmaceuticals for about $1.9 billion, the company said on Wednesday, as it looks to grow its rare disease drug portfolio.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber)
